• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合抗原受体修饰的人诱导多能干细胞来源 CD4 Treg 样细胞控制异种移植模型中的移植物抗宿主病。

Human iPSC-derived CD4 Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model.

机构信息

Shin Kaneko Laboratory, CiRA, Kyoto University, Kyoto, Japan; Takeda-CiRA joint research program (T-CiRA), Fujisawa, Kanagawa, Japan; Department of Haematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Takeda-CiRA joint research program (T-CiRA), Fujisawa, Kanagawa, Japan; T-CiRA Discovery, Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa, Japan.

出版信息

Cell Stem Cell. 2024 Jun 6;31(6):795-802.e6. doi: 10.1016/j.stem.2024.05.004.

DOI:10.1016/j.stem.2024.05.004
PMID:38848686
Abstract

CD4 T cells induced from human iPSCs (iCD4 T cells) offer a therapeutic opportunity for overcoming immune pathologies arising from hematopoietic stem cell transplantation. However, most iCD4 T cells are conventional helper T cells, which secrete inflammatory cytokines. We induced high-level expression of FOXP3, a master transcription factor of regulatory T cells, in iCD4 T cells. Human iPSC-derived, FOXP3-induced CD4 T (iCD4 Treg-like) cells did not secrete inflammatory cytokines upon activation. Moreover, they showed demethylation of the Treg-specific demethylation region, suggesting successful conversion to immunosuppressive iCD4 Treg-like cells. We further assessed these iCD4 Treg-like cells for CAR-mediated immunosuppressive ability. HLA-A2 CAR-transduced iCD4 Treg-like cells inhibited CD8 cytotoxic T cell (CTL) division in a mixed lymphocyte reaction assay with A2 allogeneic CTLs and suppressed xenogeneic graft-versus-host disease (GVHD) in NSG mice treated with A2 human PBMCs. In most cases, these cells suppressed the xenogeneic GvHD progression as much as natural CD25CD127 Tregs did.

摘要

从人诱导多能干细胞(iPSCs)诱导的 CD4 T 细胞(iCD4 T 细胞)为克服造血干细胞移植引起的免疫病理学提供了治疗机会。然而,大多数 iCD4 T 细胞是分泌炎症细胞因子的常规辅助 T 细胞。我们在 iCD4 T 细胞中诱导高水平表达 FOXP3,这是调节性 T 细胞的主转录因子。人 iPSC 衍生的、FOXP3 诱导的 CD4 T(iCD4 Treg-like)细胞在激活时不分泌炎症细胞因子。此外,它们显示出 Treg 特异性去甲基化区域的去甲基化,表明成功转化为具有免疫抑制功能的 iCD4 Treg-like 细胞。我们进一步评估了这些 iCD4 Treg-like 细胞的 CAR 介导的免疫抑制能力。HLA-A2 CAR 转导的 iCD4 Treg-like 细胞在混合淋巴细胞反应测定中抑制 A2 同种异体 CTL 的 CD8 细胞毒性 T 细胞(CTL)分裂,并抑制用 A2 人 PBMC 处理的 NSG 小鼠的异种移植物抗宿主病(GVHD)。在大多数情况下,这些细胞抑制异种移植物抗宿主病进展的程度与天然 CD25CD127 Tregs 一样。

相似文献

1
Human iPSC-derived CD4 Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model.嵌合抗原受体修饰的人诱导多能干细胞来源 CD4 Treg 样细胞控制异种移植模型中的移植物抗宿主病。
Cell Stem Cell. 2024 Jun 6;31(6):795-802.e6. doi: 10.1016/j.stem.2024.05.004.
2
HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease.HLA-A*02:01定向嵌合抗原受体/叉头框P3工程化的CD4+ T细胞呈现调节性表型并抑制已建立的移植物抗宿主病。
Cytotherapy. 2021 Feb;23(2):131-136. doi: 10.1016/j.jcyt.2020.10.002. Epub 2020 Dec 9.
3
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
4
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.宿主自然杀伤T细胞诱导供体CD4+CD25+Foxp3+调节性T细胞的白细胞介素-4依赖性扩增,从而预防移植物抗宿主病。
Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.
5
Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.表达 MHC 特异性嵌合抗原受体的人 CD8+ Tregs 可增强对 NSG 小鼠的人皮肤排斥和移植物抗宿主病的抑制作用。
Blood Adv. 2019 Nov 26;3(22):3522-3538. doi: 10.1182/bloodadvances.2019000411.
6
CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.在异基因干细胞移植后,CD4+CD25+FOXP3+调节性T细胞在多发性骨髓瘤患者的骨髓中重建并积聚。
Haematologica. 2008 Mar;93(3):423-30. doi: 10.3324/haematol.11897. Epub 2008 Feb 20.
7
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.嵌合抗原受体共刺激结构域调节人调节性 T 细胞功能。
JCI Insight. 2019 Mar 14;5(8):126194. doi: 10.1172/jci.insight.126194.
8
IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.同种异体 Foxp3+调节性 T 细胞产生 IFN-γ对于预防实验性移植物抗宿主病至关重要。
J Immunol. 2012 Sep 15;189(6):2890-6. doi: 10.4049/jimmunol.1200413. Epub 2012 Aug 6.
9
IL-34 Actions on FOXP3 Tregs and CD14 Monocytes Control Human Graft Rejection.IL-34 通过调控 FOXP3+Tregs 和 CD14+单核细胞控制人类移植物排斥反应。
Front Immunol. 2020 Aug 11;11:1496. doi: 10.3389/fimmu.2020.01496. eCollection 2020.
10
Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.输注临床级别的富含调节性 T 细胞可延迟实验性异种移植物抗宿主病。
Transfusion. 2014 Feb;54(2):353-63. doi: 10.1111/trf.12279. Epub 2013 Jun 17.

引用本文的文献

1
Integrating Macrophages into Human-Engineered Cardiac Tissue.将巨噬细胞整合到人类工程心脏组织中。
Cells. 2025 Sep 6;14(17):1393. doi: 10.3390/cells14171393.
2
MDM4 enables efficient human iPS cell generation from PBMCs using synthetic RNAs.MDM4可利用合成RNA从外周血单个核细胞高效生成人诱导多能干细胞。
Sci Rep. 2025 Sep 8;15(1):30620. doi: 10.1038/s41598-025-16446-y.
3
Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions.全球自身免疫性疾病干细胞治疗临床试验:趋势与未来方向
Front Immunol. 2025 Jul 24;16:1616231. doi: 10.3389/fimmu.2025.1616231. eCollection 2025.
4
Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy.应对用于过继性细胞治疗的调节性T细胞在制造、测试及监管方面的复杂性。
Front Immunol. 2025 Jul 16;16:1626085. doi: 10.3389/fimmu.2025.1626085. eCollection 2025.
5
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.解决癌症异基因细胞免疫治疗中的移植物抗宿主病问题。
Exp Hematol Oncol. 2025 May 2;14(1):66. doi: 10.1186/s40164-025-00654-3.
6
Cell therapies for immune-mediated disorders.用于免疫介导性疾病的细胞疗法。
Front Med (Lausanne). 2025 Mar 26;12:1550527. doi: 10.3389/fmed.2025.1550527. eCollection 2025.
7
Pluripotent stem cell-based immunotherapy: advances in translational research, cell differentiation, and gene modifications.基于多能干细胞的免疫疗法:转化研究、细胞分化和基因修饰的进展
Life Med. 2025 Jan 18;4(1):lnaf002. doi: 10.1093/lifemedi/lnaf002. eCollection 2025 Feb.
8
iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment.诱导多能干细胞技术革新了用于癌症治疗的嵌合抗原受体T细胞疗法。
Bioengineering (Basel). 2025 Jan 13;12(1):60. doi: 10.3390/bioengineering12010060.
9
Oral GVHD post-cardiac xenograft valve replacement: a case report.心脏异种移植瓣膜置换术后口腔移植物抗宿主病:一例报告
J Cardiothorac Surg. 2024 Dec 26;19(1):682. doi: 10.1186/s13019-024-03200-0.
10
Harnessing the biology of regulatory T cells to treat disease.利用调节性T细胞的生物学特性治疗疾病。
Nat Rev Drug Discov. 2025 Feb;24(2):93-111. doi: 10.1038/s41573-024-01089-x. Epub 2024 Dec 16.